公开(公告)号：US20230032293A1

公开(公告)日：2023-02-02

申请号：US17881413

申请日：2022-08-04

Applicant: ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Daisuke Kajita ,  Kotoe Tamada

IPC: A61K35/28 ,  A61P9/10 ,  A61K9/06 ,  A61K9/08 ,  A61K38/36 ,  A61K38/48 ,  A61K9/12 ,  A61K9/10 ,  A61P9/00 ,  A61K38/00 ,  A61P27/02 ,  A61P43/00

Abstract: Methods are described for treating a heart disease, comprising suspending c) mesenchymal stem cells in either a) a fibrinogen solution or b) a thrombin solution, thereby obtaining a cell suspension, and directly spraying the cell suspension on a disease site substantially at the same time with the other of a) the fibrinogen solution or b) the thrombin solution that is not used in the suspending.

公开(公告)号：US12226436B2

公开(公告)日：2025-02-18

申请号：US16071123

申请日：2017-01-18

Applicant: ROHTO PHARMACEUTICAL CO., LTD

Inventor： Daisuke Kajita ,  Satsuki Fukushima ,  Shigeru Miyagawa ,  Yoshiki Sawa

IPC: A61K35/28 ,  A61K35/35 ,  A61K35/51 ,  A61K35/545

Abstract: It has been found that a cell cluster obtained by causing just isolated cells to adhere to each other secretes adiponectin after transplantation to the heart, and thereby has an excellent therapeutic effect on heart disease.

公开(公告)号：US20200171092A1

公开(公告)日：2020-06-04

申请号：US16620655

申请日：2018-05-08

Applicant: OSAKA UNIVERSITY ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Daisuke Kajita ,  Hayato Kurata ,  Kotoe Tamada ,  Hiroyuki Nishida

IPC: A61K35/28 ,  A61K9/14 ,  A61K38/20 ,  A61K38/18 ,  A61K38/17 ,  A61P9/10

Abstract: The purpose of the present invention is to provide a therapeutic agent for dilated cardiomyopathy disease which produces excellent effects in the treatment of dilated cardiomyopathy (DCM) and provides a given benefit to a large number of patients. The present invention is a therapeutic agent for dilated cardiomyopathy comprising at least one selected from the group consisting of mesenchymal stem cell and microparticles derived from the mesenchymal stem cell. It is preferable that the mesenchymal stem cell is a cell having the ability to contain or secrete microparticles, that the microparticles have an average particle size of 1000 nm or less, and that they are exosomes.

公开(公告)号：US20190255116A1

公开(公告)日：2019-08-22

申请号：US16343330

申请日：2017-10-13

Applicant: OSAKA UNIVERSITY ,  ROHTO PHARMACEUTICAL CO., LTD.

Inventor： Yoshiki Sawa ,  Shigeru Miyagawa ,  Daisuke Kajita ,  Kotoe Tamada

IPC: A61K35/28 ,  A61K9/06 ,  A61K38/48 ,  A61K38/36 ,  A61K9/08 ,  A61P9/10

Abstract: The present invention addresses the problem of providing a disease-treating agent which exerts an excellent effect in treating diseases requiring an emergency surgery such as heart failure and which is efficacious at a certain level for a large number of patients. The present invention pertains to a kit for preparing a disease-treating agent, said kit comprising a) a fibrinogen solution, b) a thrombin solution and c) mesenchymal stem cells, in separate forms respectively. It is preferred that c) the mesenchymal stem cells are allogeneic to a subject to be treated. Also, the present invention pertains to a kit for preparing a disease-treating agent, said kit being to be used by, when in use, suspending c) the mesenchymal stem cells in either a) the fibrinogen solution or b) the thrombin solution, and then spraying the cell suspension thus obtained directly to a disease site substantially simultaneously with either b) the thrombin solution or a) the fibrinogen solution that is not used in the suspending step.